Full Library
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Resource type
Journal Article
Authors/contributors
- Ullmann, Andrew J. (Author)
- Lipton, Jeffrey H. (Author)
- Vesole, David H. (Author)
- Chandrasekar, Pranatharthi (Author)
- Langston, Amelia (Author)
- Tarantolo, Stefano R. (Author)
- Greinix, Hildegard (Author)
- Morais de Azevedo, Wellington (Author)
- Reddy, Vijay (Author)
- Boparai, Navdeep (Author)
- Pedicone, Lisa (Author)
- Patino, Hernando (Author)
- Durrant, Simon (Author)
Title
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Abstract
This randomized, double-blind trial of prophylaxis to prevent invasive fungal infections was conducted in 600 patients with severe graft-versus-host disease after hematopoietic stem-cell transplantation. Posaconazole, an extended-spectrum triazole, was as effective as fluconazole in preventing invasive fungal infections (incidence, 5.3% and 9.0%, respectively). With posaconazole, there were fewer cases of invasive aspergillosis infections.
Publication
New England Journal of Medicine
Date
January 25, 2007
Volume
356
Issue
4
Pages
335-347
Accessed
11/1/18, 3:47 PM
ISSN
0028-4793
Library Catalog
Taylor and Francis+NEJM
Extra
PMID: 17251530
Citation
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H., & Durrant, S. (2007). Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. New England Journal of Medicine, 356(4), 335–347. https://doi.org/10.1056/NEJMoa061098
DRUGS AND THERAPIES
HEME-ONC AND CELLULAR THERAPIES
Link to this record